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myeloid cells-1 for diagnosing ventilator-
associated pneumonia after cardiac surgery: an
observational study
Alessandra K Matsuno1 and Ana PCP Carlotti1,2*
Abstract
Background: The diagnosis of ventilator-associated pneumonia (VAP) is a challenge, particularly after cardiac
surgery. The use of biological markers of infection has been suggested to improve the accuracy of VAP diagnosis.
We aimed to evaluate the usefulness of soluble triggering receptor expressed on myeloid cells (sTREM)-1 in the
diagnosis of VAP following cardiac surgery.
Methods: This was a prospective observational cohort study of children with congenital heart disease admitted to
the pediatric intensive care unit (PICU) after surgery and who remained intubated and mechanically ventilated for
at least 24 hours postoperatively. VAP was defined by the 2007 Centers for Disease Control and Prevention criteria.
Blood, modified bronchoalveolar lavage (mBAL) fluid and exhaled ventilator condensate (EVC) were collected daily,
starting immediately after surgery until the fifth postoperative day or until extubation for measurement of sTREM-1.
Results: Thirty patients were included, 16 with VAP. Demographic variables, Pediatric Risk of Mortality (PRISM) and
Risk Adjustment for Congenital Heart Surgery (RACHS)-1 scores, duration of surgery and length of cardiopulmonary
bypass were not significantly diferent in patients with and without VAP. However, time on mechanical ventilation
and length of stay in the PICU and in the hospital were significantly longer in the VAP group. Serum and mBAL
fluid sTREM-1 concentrations were similar in both groups. In the VAP group, 12 of 16 patients had sTREM-1 detected
in EVC, whereas it was undetectable in all but two patients in the non-VAP group over the study period (p = 0.0013)
(sensitivity 0.75, specificity 0.86, positive predictive value 0.86, negative predictive value 0.75, positive likelihood ratio
(LR) 5.25, negative LR 0.29).
Conclusion: Measurement of sTREM-1 in EVC may be useful for the diagnosis of VAP after cardiac surgery.
Keywords: Triggering receptor expressed on myeloid cells-1, Ventilator-associated pneumonia, Diagnosis,
Cardiac surgery, Postoperative
Background
Ventilator-associated pneumonia (VAP) is the most com-
mon nosocomial infection in children following cardiac sur-
gery in Brazil and European countries [1-3]. Its reported
incidence ranges from 17.1 to 42.8 episodes per 1000
ventilator-days and it is associated with increased duration
of mechanical ventilation, increased length of pediatric in-
tensive care unit (PICU) and hospital stay and higher mor-
tality rates [1,2,4].
The diagnosis of VAP is a major challenge in patients
undergoing cardiac surgery, because the systemic inflam-
matory response syndrome elicited by surgical trauma and
the interaction of blood with the cardiopulmonary bypass
(CPB) circuit may induce symptoms that are similar to
those caused by systemic infections [5]. In addition,
imaging studies may show pulmonary opacities caused by
fluid overload, capillary leak, pulmonary contusion re-
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sulting from surgical manipulation, atelectasis or alveolar
hemorrhage, which are comparable to those found in pa-
tients with pneumonia. Although in critically ill patients
with severe bacterial infections early initiation of appropri-
ate antibiotic therapy is crucial for survival, in patients with
the systemic inflammatory response syndrome associated
with non-infectious processes unnecessary treatment with
antibiotics may lead to increased bacterial resistance and in-
creased costs, with no treatment benefit. This highlights the
importance of making an accurate diagnosis of VAP.
The gold standard method for diagnostic confirmation of
VAP is lung tissue examination and culture [6,7], but its
clinical applicability is limited. The clinical and radiologic
criteria recommended by the Centers for Disease Control
and Prevention (CDC) have limited specificity whereas the
microbiological criteria lack specificity and sensitivity
compared with autopsy lung culture [6]. Thus, the use of
biological markers of infection as the triggering receptor
expressed on myeloid cells (TREM)-1 has been suggested
to improve the accuracy of the diagnosis of VAP [8-10].
TREM-1 is a transmembrane glycoprotein expressed on
neutrophils, macrophages and monocytes that amplifies the
inflammatory response. Its expression by the effector cells is
upregulated in tissues infected by bacteria and fungi [11].
The activation of TREM-1 stimulates the production of
proinflammatory cytokines and induces neutrophil degranu-
lation and oxidative burst [12]. Moreover, infection induces
the release of a soluble form of this receptor from the
membranes of activated phagocytes (sTREM-1) which can
be measured in body fluids and may be a useful diagnostic
tool [13]. It has been shown that plasma sTREM-1 con-
centrations are increased in patients with sepsis [14]. In
addition, elevated levels of TREM-1 have been found in
bronchoalveolar lavage (BAL) fluid and in the fluid collected
from the ventilator expiratory trap, the exhaled ventilator
condensate (EVC), in critically ill adults with VAP [8-10].
However, increased plasma concentrations of TREM-1 have
also been reported in patients with the systemic inflamma-
tory response syndrome secondary to cardiac surgery with
CPB and after cardiac arrest, without infection [15]. Never-
theless, there are no published data on the role of sTREM-1
in the diagnosis of VAP in patients undergoing cardiac
surgery. To address this question, we performed serial mea-
surements of sTREM-1 concentrations in serum, modified
non-bronchoscopic bronchoalveolar lavage (mBAL) fluid
and EVC samples in intubated and mechanically ventilated
children following cardiac surgery. We sought to evaluate
whether the use of sTREM-1 could improve the accuracy of
VAP diagnosis after cardiac surgery.
Methods
Study design and patients
This was a prospective cohort study conducted in a PICU
of a tertiary-care university hospital in Brazil. The study
was approved by the Research Ethics Board of Hospital das
Clínicas of Ribeirão Preto Medical School, University of
São Paulo (#1499/2008) and written informed consent was
obtained from the patients’ parents. Children with congeni-
tal heart disease admitted to the PICU following cardiac
surgery from May 2008 to April 2009 and who remained
intubated and mechanically ventilated for at least 24 hours
after surgery were eligible for the study. Exclusion criteria
were a preoperative diagnosis of nosocomial pneumonia
and/or sepsis, death in the first 24 postoperative hours and
refusal to participate.
Patients received prophylactic antibiotics for 48 hours
from the induction of anesthesia with intravenous cefazolin
(40 mg/kg every 8 hours) and amikacin (7.5 mg/kg every
12 hours). Patients with a history of hospitalization for
more than 72 hours, ICU admission or previous use of
antibiotics received intravenous vancomycin (20 mg/kg at
the induction of anesthesia followed by 10 mg/kg every
6 hours) and amikacin (7.5 mg/kg every 12 hours).
Patients who underwent CPB received a bolus dose of
30 mg/kg of methylprednisolone or 10 mg/kg of hydro-
cortisone at CPB start. Modified ultrafiltration was not
performed at the end of CPB.
The diagnosis of VAP was made independently by the
PICU physician and an infection control practitioner by the
2007 CDC criteria, which considered that no minimum
period of time was needed for the ventilator to be in place
to diagnose VAP. According to the time of onset, VAP was
categorized as early, when it occurred within 1 to 4 days of
mechanical ventilation, and late, when it occurred after
4 days of ventilation [6].
Data collection
Demographic and clinical data were collected from
patients’ health records. Procedure complexity was strati-
fied according to Risk Adjustment for Congenital Heart
Surgery (RACHS)-1 score [16] and severity of illness was
assessed by Pediatric Risk of Mortality (PRISM) score be-
tween 8 and 24 hours following PICU admission [17].
Blood, mBAL fluid and EVC were collected daily, starting
immediately after surgery (iPO) until the fifth postoperative
day (POD5) or until the child was extubated for measure-
ment of sTREM-1 by a sandwich enzyme-linked immuno-
sorbent assay (ELISA – kit Quantikine – R&D Systems,
Minneapolis, MN, USA). Blood samples were collected
from arterial lines inserted before surgery for blood pres-
sure monitoring. mBAL fluid was collected using a feeding
tube, which was introduced down the endotracheal tube
until resistance was felt. Then, using a syringe, 1 ml/kg of
normal saline (maximum 20 ml) was instilled through the
feeding tube followed by a small amount of air to clear the
deadspace of the catheter and suction was applied to obtain
the fluid [18]. Quantitative cultures of mBAL fluid were
considered positive when the growth of >105 CFU/mL was
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observed [19]. EVC (approximately 1 ml) was collected
from the trap located in the expiratory limb of the ventila-
tor circuit [10]. Nasopharyngeal aspirates were collected
from all patients for detection of respiratory viruses by real-
time PCR using a standard protocol [20].
Statistical analysis
Analysis was made using GraphPad Prism 5.0 (San Diego,
CA) and SAS 9.2, R 2.15.1 (SAS/STAT® User’s Guide,
Version 9.2, Cary, NC: SAS Institute Inc., 2008). Data were
expressed as median (range). Patients were grouped accord-
ing to the presence or absence of VAP. Continuous vari-
ables between groups were compared by Mann–Whitney
U test and categorical variables by Fisher’s exact test.
Variables with repeated measurements (serum and mBAL
sTREM-1) were analyzed after logarithmic transformation
using a linear mixed-effects model where individual mea-
sures over time were included as a random factor and
group membership and time as fixed factors. Because there
were many undetectable values of EVC sTREM-1 concen-
trations, they were categorized as positive and negative, and
analysed by Fisher’s exact test. Association between vari-
ables was assessed by Spearman’s correlation. A Receiver
Operating Characteristic (ROC) curve was constructed for
determination of cut-off value of sTREM-1 in serum,
mBAL and EVC for the diagnosis of VAP, considering
values on the day of VAP diagnosis for the VAP group and
the largest value over the study period for the non-VAP
group, since increased concentrations of sTREM-1 could
also be related to the systemic inflammatory response to
surgery and CPB, and pulmonary congestion. A p value
< 0.05 was considered significant.
Results
Characteristics of the patients
Over the study period, 145 children with congenital heart
disease were admitted to the PICU of our institution after
cardiac surgery; 63 met the inclusion criteria. Thirty
patients were excluded because consent was not obtained
and three because of death in iPO. Thirty patients were
included in the study. Their median age was 45 days (range
2 to 4015 days) and their median weight 3.4 kg (range 1.8
to 20 kg). Twenty-six (87%) patients underwent CPB. Seven
(23%) patients were left with the sternum open for 2 to
5 days after surgery (median 4 days). Twenty-eight (93%)
patients had pulmonary congestion in iPO.
Of the 30 patients included, 16 (53%) developed VAP,
which was diagnosed between the first and the fifth post-
operative day; the median time to VAP diagnosis was 2 days
after surgery. All but one patient had early-onset VAP. The
rate of VAP at our PICU during the study period was 22.8
episodes per 1000 ventilator-days. Table 1 shows compari-
sons between patients with and without VAP. Demographic
variables, PRISM and complexity of surgery assessed by
RACHS-1 score were similar in both groups. Also, duration
of surgery and length of cardiopulmonary bypass were not
significantly diferent in patients with and without VAP.
However, time on mechanical ventilation and length of stay
in the PICU and in the hospital were significantly longer in
the VAP group. There were two deaths within 28 days of
admission, both in the VAP group, due to septic shock.
mBAL culture was positive (considering the cutoff
of > 105 CFU/mL) in six patients with VAP, with the
growth of the following agents: Acinetobacter baumannii
(n = 2), Staphylococcus epidermidis (n = 1), Staphylococcus
aureusmethicillin-sensitive (n = 1), Pseudomonas aeruginosa
(n = 1), and Enterococus faecium (n = 1). Blood culture was
positive in two patients with VAP, with the growth of
Staphylococcus aureus methicillin-sensitive (n = 1; the same
microorganism grew in mBAL fluid) and Staphylococcus
aureus methicillin-resistant (n = 1). Bocavirus was detected
in nasopharyngeal aspirate in one patient with VAP and
rhinovirus was detected in five patients in the VAP group
and in three patients in the non-VAP group. Three patients
with rhinovirus infection in the VAP group were coinfected
with the following agents: Acinetobacter baumannii, S.
aureus methicillin-sensitive and S. aureus methicillin-
resistant; one patient in the non-VAP group was coinfected
with respiratory syncytial virus. mBAL and blood cultures
were negative in all patients in the non-VAP group.
sTREM-1measurements
There was no significant difference between groups in daily
serum sTREM-1 concentrations and values did not change
significantly over time in either group (p = 0.25). Peak serum
sTREM-1 concentrations were observed on POD3 in
patients with VAP (median 379 pg/ml; range 74–888 pg/ml)
and POD2 in patients without VAP (median: 267 pg/ml;
range: 75–411 pg/ml). In the group with VAP, comparison
of serum concentrations of sTREM-1 on the day of VAP
diagnosis (D0) with those on the day before (D-1) and on
the day after (D+1) the diagnosis of VAP did not show a
significant difference (p = 0.71) (Figure 1). Comparison of
serum sTREM-1 concentrations on the day of VAP diag-
nosis with peak serum sTREM-1 concentrations in the non-
VAP group also did not show a significant difference (p =
0.16). There was no correlation of serum sTREM-1 peak
concentrations with duration of CPB (r = 0.08; p = 0.65) or
duration of aortic cross-clamping time (r = −0.07; p = 0.72).
No significant differences in daily sTREM-1 concentra-
tions in mBAL fluid were observed between groups and
values did not change significantly over time in either group
(p = 0.5). Peak concentrations of sTREM-1 in mBAL fluid
occurred in patients with VAP on POD1 (median 2414
pg/ml; range 60–11576 pg/ml) and in patients without VAP
on POD5 (median 3827 pg/ml; range 693–6187 pg/ml).
In the group with VAP, comparison of concentrations of
sTREM-1 in mBAL fluid on the day of VAP diagnosis (D0)
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with those on the day before (D-1) and on the day after
(D+1) the diagnosis of VAP did not show a significant differ-
ence (p = 0.24) (Figure 2). Comparison of sTREM-1 con-
centrations in mBAL fluid on the day of VAP diagnosis with
peak sTREM-1 concentrations in mBAL fluid in the non-
VAP group also did not show a significant difference
(p = 0.34).
Peak sTREM-1 concentrations in EVC were observed
in the VAP group on POD3 (median 11.5 pg/ml; range
0–163 pg/ml). In the non-VAP group, only two patients had
detectable concentrations of sTREM-1 in EVC: one patient
on POD4 (43 pg/ml) and POD5 (195 pg/ml) and the other
on iPO (14 pg/ml), POD1 (17 pg/ml) and POD2 (49 pg/ml)
(Figure 3). Both patients subsequently developed a surgical
site infection. Twelve of 16 (75%) patients who developed
VAP had sTREM-1 detected in EVC on the day of VAP
diagnosis and/or the preceding day, while it was detectable
in only 2 of 14 (14.3%) patients in the non-VAP group over
Table 1 Characteristics of the study groups
Characteristics Patients with VAP (n = 16) Patients without VAP (n =14) P value
Age (days) 32 (3–2310) 49 (3–4015) 0.72
Weight (kg) 3.3 (1.8–17.3) 3.8 (2.2–20) 0.83
Male gender 8 (50%) 6 (43%) 0.73
PRISM 11 (4–28) 11 (2–17) 0.23
RACHS-1 4 (2–6) 4 (2–4) 0.65
Use of CPB 14 (88%) 12 (86%) 1
Duration of CPB (minutes) 110 (0–175) 120 (0–160) 0.38
Aortic cross clamp time (minutes) 60 (0–99) 87 (0–113) 0.17
Duration of surgery (minutes) 238 (145–495) 248 (165–410) 0.52
Duration of mechanical ventilation after surgery (days) 8 (3–19) 3 (1–7) 0.0004
PICU length of stay (days) 15 (5–31) 7 (4–16) 0.004
Hospital length of stay (days) 30 (9–218) 12 (7–27) 0.006
Mortality 2 (12.5%) 0 0.48
Legend: Data are reported as median (range) or n (%). PRISM, Pediatric Risk of Mortality; RACHS, Risk Adjustment for Congenital Heart Surgery; CPB, cardiopulmonary bypass;
PICU, pediatric intensive care unit.
Figure 1 Serum concentrations of soluble triggering receptor expressed on myeloid cells (sTREM)-1. A. Daily log-transformed serum
concentrations of sTREM-1 in the ventilator-associated pneumonia (VAP) group (white boxes) and in the non-VAP group (boxes with gray shading).
B. Serum concentrations of sTREM-1 in the VAP group on the day before VAP diagnosis (D-1), on the day of VAP diagnosis (D0) and on the day after
VAP diagnosis (D+1). Central lines are medians, boxes are interquartile ranges, and brackets are total range.
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the study period (p = 0.0013) (sensitivity 0.75, 95% CI 0.48-
0.93; specificity 0.86, 95% CI 0.57-0.98; positive predictive
value 0.86, 95% CI 0.57-0.98; negative predictive value 0.75,
95% CI 0.48-0.93; positive likelihood ratio (LR) 5.25, 95% CI
3.99-6.9; negative LR 0.29, 95% CI 0.22-0.39). A cut-off value
of 20.58 pg/ml of sTREM-1 in EVC on the day of VAP
diagnosis had a sensitivity of 0.50 (95% CI 0.26-0.75) and a
specificity of 0.86 (95% CI 0.56-0.98) for the diagnosis of
VAP (area under the ROC curve 0.67; 95% CI 0.48-0.86)
(Figure 4). Serum and mBAL sTREM-1 yielded areas under
the ROC curve 0.60 and 0.42, respectively (data not shown).
Discussion
In the present study, we investigated the usefulness of serial
measurements of sTREM-1 in serum, mBAL fluid and
Figure 2 Concentrations of soluble triggering receptor expressed on myeloid cells (sTREM)-1 in modified non-bronchoscopic bronchoalveolar
lavage (mBAL) fluid. A. Daily log-transformed concentrations of sTREM-1 in mBAL fluid in the ventilator-associated pneumonia (VAP) group (white boxes)
and in the non-VAP group (boxes with gray shading). B. Concentrations of sTREM-1 in mBAL fluid in the VAP group on the day before VAP diagnosis
(D-1), on the day of VAP diagnosis (D0) and on the day after VAP diagnosis (D+1). Central lines are medians, boxes are interquartile ranges, and brackets
are total range.
Figure 3 Daily concentrations of soluble triggering receptor
expressed on myeloid cells (sTREM)-1 in exhaled ventilator
condensate (EVC) in the ventilator-associated pneumonia (VAP)
group (white boxes) and in the non-VAP group (boxes with gray
shading). Central lines are medians, boxes are interquartile ranges, and
brackets are total range.
Figure 4 Receiver Operating Characteristic curve for soluble
triggering receptor expressed on myeloid cells (sTREM)-1 levels in
exhaled ventilator condensate on the day of ventilator-associated
pneumonia diagnosis.
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EVC for the diagnosis of VAP in children after congenital
heart surgery. This is the first study to evaluate the diagnos-
tic value of sTREM-1 in VAP following cardiac surgery.
Our results showed that measurement of sTREM-1 in the
EVC can be useful for diagnosing VAP in this population.
However, sTREM-1 measurements in serum and mBAL
fluid did not discriminate patients with VAP from those
without VAP following cardiac surgery.
A previous study showed that plasma sTREM-1 concen-
trations increased after surgery in noninfected patients
undergoing elective cardiac surgery with CPB and peak
plasma levels of sTREM-1 overlapped with those found in
patients with severe sepsis. However, no correlation was
observed between sTREM-1 plasma concentrations and
CPB duration or aortic cross-clamping time [15]. Our re-
sults corroborate these findings which suggest that elevated
serum levels of sTREM-1 may also be related to the
systemic inflammatory response to surgical stress.
In critically ill mechanically ventilated adults who devel-
oped VAP, plasma sTREM-1 levels did not change signifi-
cantly over time. Nevertheless, a significant increase in
mBAL fluid sTREM-1 concentration was observed. A cut-
off value of 200 pg/ml combined with an increase of at least
100 pg/ml over the 6-day period before VAP was diagnosed
had a sensitivity of 88% and a specificity of 84% for the diag-
nosis of VAP [9]. In addition, levels of sTREM-1 in BAL
fluid were significantly higher in adults receiving mechanical
ventilation with community-acquired pneumonia and VAP
compared with patients without pneumonia [8]. In contrast,
in critically ill adults with acute respiratory failure under-
going BAL for pulmonary infiltrates, the concentration of
sTREM-1 in BAL fluid was not significantly greater in those
with definite VAP, with the highest sTREM-1 concentrations
being observed in patients with alveolar hemorrhage [21].
Accordingly, in our study, sTREM-1 concentrations in
mBAL fluid were not significantly different in patients with
and without VAP. Moreover, we did not observe significant
changes in mBAL sTREM-1 levels from the day before to
the day after VAP diagnosis. As more than 90% of patients
had pulmonary congestion in the postoperative period, this
could have altered sTREM-1 levels in mBAL fluid in our
study.
Our data suggest that measurement of sTREM-1 in
EVC may improve the accuracy of the diagnosis of VAP,
which is in agreement with findings from a previous study
in adults in a medical ICU, with a clinical suspicion of
VAP [10]. In our study, sTREM-1 measurement in EVC
samples had a good discriminative value to differentiate
patients with VAP from those without VAP. Indeed, a
positive test result rather than a cutoff value of sTREM-1
concentration in EVC was associated with a high proba-
bility of VAP being present (likelihood ratio of 5.2). This is
especially important for patients following cardiac surgery
who can have pulmonary opacities on the chest x-ray
caused by multiple noninfectious conditions that may be
misdiagnosed as pneumonia. In addition, EVC samples
can be easily collected in a noninvasive way.
The major limitation of our study is the lack of a gold
standard method for the diagnosis of VAP. However, there
is currently no gold standard for the diagnosis of VAP in
the clinical setting [22]. Other limitation is the lack of
measurements of sTREM-1 concentrations before surgery
to determine the baseline patients’ levels.
Conclusion
The detection of sTREM-1 in EVC samples may be useful
for the diagnosis of VAP after heart surgery.
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